Tacrolimus for myasthenia gravis: A clinical study of 212 patients

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 254-263

  Ponseti, José M ^a   Gamez, Josep ^a   Azem, Jamal ^a   López Cano, Manuel ^a   Vilallonga, Ramón ^a   Armengol, Manuel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Immunosuppressive agents; Muscle weakness; Myasthenia gravis; Postoperative period; Prednisone; Tacrolimus

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CYCLOSPORIN; PREDNISONE; TACROLIMUS;

ACNE; ADULT; AGED; ANEMIA; ATAXIA; AUTOIMMUNE DISEASE; CLINICAL STUDY; CONFERENCE PAPER; CONTROL GROUP; CONTROLLED STUDY; CUSHING SYNDROME; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERTROPHY; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERPLASIA; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; INFECTION; KIDNEY CANCER; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MUSCLE STRENGTH; MYASTHENIA GRAVIS; NEPHROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; REMISSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; THYMECTOMY; THYMOMA; TREATMENT DURATION; TREMOR; VISUAL HALLUCINATION;

EID: 45249113081     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.000     Document Type: Conference Paper

References (30)

1. Conti-Fine, B.M., M. Milani & H.J. Kaminski. 2006. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 : 2843 2854.
2. Sieb, J.P. 2005. Myasthenia gravis: emerging new therapy options. Curr. Opin. Pharmacol. 5 : 303 307.
3. Ciafaloni, E. 2005. Mycophenolate mofetil and myasthenia gravis. Lupus 14 (Suppl 1 S46 S49.
4. Ponseti, J.M., J. Azem, J.M. Fort, et al. 2005. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin. Neurol. Neurosurg. 107 : 187 190.
5. Ponseti, J.M., J. Azem, J.M. Fort, et al. 2005. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 64 : 1641 1643.
6. Ponseti, J.M., J. Azem, J.M. Fort, et al. 2006. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis. Curr. Med. Res. Opin. 22 : 885 895.
7. Ponseti, J.M., J. Gamez, J. Azem, et al. 2007. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: A non-randomized, non-controlled study. Curr. Med. Res. Opin. 23 : 1269 1278.
8. Masaoka, A., Y. Yamakawa, H. Niwa, et al. 1996. Extended thymectomy for myasthenia gravis patients: A 20-year review. Ann. Thorac. Surg. 62 : 853 859.
9. López-Cano, M., J.M. Ponseti-Bosch, E. Espin-Basany, et al. 2003. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann. Thorac. Surg. 76 : 1643 1649.
10. Jaretzki, A. 3rd., R.J. Barohn, R.M. Ernstoff, et al. 2000. Myasthenia gravis: recommendations for clinical research standards [Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America]. Neurology 55 : 16 23.
11. Masaoka, A., Y. Monden, H.K. Nakahara, et al. 1981. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48 : 2485 2492.
12. Ponseti, J.M. 1995. Miastenia gravis. Manual terapéutico. Springer Verlag. Barcelona.
13. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 : 457 481.
14. Wakata, N., T. Saito, S. Tanaka, et al. 2003. Tacrolimus hydrate (FK506): Therapeutic effects and selection of responders in the treatment of myasthenia gravis. Clin. Neurol. Neursurg. 106 : 5 8.
15. Konishi, T., Y. Yoshiyama, M. Takamori, et al. 2005. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J. Neurol. Neurosurg. Psychiatry 76 : 448 450.
16. Nagane, Y., K. Utsugisawa, F. Obara, et al. 2005. Efficacy of low-dose FK506 in the tretament of myasthenia gravis-a randomized pilot study. Eur. Neurol. 53 : 146 150.
17. Evoli, A., P.A. Tonali, L. Padua, et al. 2003. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126 : 2304 231.
18. Tada, M., T. Shimohata, M. Tada, et al. 2006. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J. Neurol. Sci. 247 : 17 20.
19. Shimojima, Y., M. Matsuda, T. Gono, et al. 2006. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone. J. Clin. Neurosc. 13 : 39 44.
20. Kawaguchi, N., Y. Yoshiyama, Y. Nemoto, et al. 2004. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr. Med. Res. Opin. 20 : 1269 1273.
21. Mitsui, T., M. Kunishige, M. Ichimiya, et al. 2007. Beneficial effect of tacrolimus on myasthenia gravis with thymoma. Neurologist 13 : 83 86.
22. Sekine, Y., N. Kawaguchi, C. Hamada, et al. 2006. Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis? Eur. J. Cardiothorac. Surg. 29 : 908 913.
23. Antín, J.H., H.T. Kim, C. Cutler, et al. 2003. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102 : 1601 1605.
24. Timerman, A.P., E. Ogubumni, E. Freund, et al. 1993. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 268 : 22992 22999.
25. Mayrleitner, M., A.P. Timerman, G. Wiederrecht, et al. 1994. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506 binding protein: effect of FKBP-12 on single channel activity of the skeletal muscle ryanodine receptor. Cell Calcium 15 : 99 108.
26. Nemoto, Y., S. Kuwabara, S. Misawa, et al. 2005. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 76 : 714 718.
27. Takamori, M., M. Motomura, N. Kawaguchi, et al. 2004. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 62 : 1894 1896.
28. Davies, T.H., Y.M. Ning, E.R. Sánchez, et al. 2005. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 44 : 2030 2038.
29. Kang, C.B., L. Feng, J. Chia, et al. 2005. Molecular characterization of FK-506 binding protein 38 and its potential regulatory role on the anti-apoptotic protein Bcl-2. Biochem. Biophys. Res. Commun. 337 : 30 38.
30. Migita, K. & K. Eguchi. 2001. FK 506-mediated T-cell apoptosis induction. Transplant. Proc. 33 : 2292 2293.